Visalytics
Visalytics
approved EB-2 (NIW)

Scientist

Molecular Biology · Russia · 2025-02-27

Processing Time
51 days
Decision Date
2025-02-27
Location
Oregon
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to develop a deterministic model using epigenetic signatures to identify individuals at high risk for the onset and relapse of acute myeloid leukemia (AML). This research focuses on advancing precision in early diagnosis through complex molecular profiling to pinpoint early biological markers. The work aims to enable targeted clinical interventions before symptoms escalate, thereby reducing mortality and healthcare disparities associated with aggressive blood cancers.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The endeavor addresses acute myeloid leukemia detection and treatment, which supports national healthcare goals and benefits patients worldwide.

2 Well-positioned to Advance the Endeavor Met

The petitioner's record of 1,078 citations, 11 peer-reviewed articles, and support from the American Cancer Society demonstrates his readiness to lead this research.

3 On Balance, Beneficial to Waive Job Offer Met

The petitioner's unique expertise in epigenetic signatures and deterministic modeling makes his continued presence in the U.S. beneficial regardless of a specific job offer.

Why This Petition Was Approved

The petition was approved based on the petitioner's significant contributions to molecular biology, including 11 peer-reviewed journal articles and 1,078 total citations. The case demonstrated national importance through research supported by the American Cancer Society and expert testimonials confirming the petitioner's unique value to the field. All three Dhanasar prongs were satisfied through a combination of high-impact publications and specialized expertise in DNA methylation analysis.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Conference Presentations
Grants
Reference Letters Dependent
Original Contributions

Similar Cases

Research Fellow

Biotechnology · India

WeGreened EB-2 (NIW) approved
Massachusetts 111 days 2023-03-23
The petitioner proposes to continue her research in biomedical sciences, specifically optimizing therapeutic strategies for acute myeloid leukemia by elucidating molecular mechanisms. Her work focuses on identifying leukemia stem cell markers and critical transcription factors to develop advanced treatment strategies for therapy-resistant quiescent stem cells in blood cancer.
View Case

Postdoctoral Researcher

Biotechnology · United Kingdom

WeGreened EB-2 (NIW) approved
Maryland 58 days 2025-08-01
The petitioner proposes to continue her research in epigenetics, specifically focusing on the molecular mechanisms of carcinogenesis in colon and lung cancers. She utilizes next-generation sequencing to identify DNA methylation markers that serve as early indicators of cancer recurrence or as novel therapeutic targets.
View Case

Scientist

Biotechnology · Turkey

WeGreened EB-2 (NIW) approved
Massachusetts 452 days 2022-05-26
The petitioner proposes to continue her research on large-scale genetics and biomolecular datasets to discover disease-driver mechanisms and identify therapeutic targets. Her work focuses on developing personalized, cost-effective diagnostics and therapies for diseases such as cancer, specifically multiple myeloma, by training algorithms to analyze genetic data.
View Case

Assistant Professor

Healthcare · China

WeGreened EB-2 (NIW) approved
Pennsylvania 40 days 2025-05-13
The petitioner proposes to enhance CAR-T cell therapy for hematological malignancies by integrating laboratory research with patient-centered clinical trials. The work focuses on closing the translational gap to bring immunotherapy discoveries into clinical practice for leukemia and other blood cancers. The goal is to develop therapies that are more precise, responsive, and accessible to patients.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Biotechnology cases More cases from Russia

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-02-27.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 51 days
Criteria Met 3 / 3
Evidence Types 6

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,813
Success Rate 53.7%
Sustained 2,046
Dismissed 1,671

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Russia All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist